Lifespot Capital AG (früher CDC Capital AG) (Seite 9)
eröffnet am 13.11.06 12:43:02 von
neuester Beitrag 13.01.23 11:58:08 von
neuester Beitrag 13.01.23 11:58:08 von
Beiträge: 1.024
ID: 1.093.910
ID: 1.093.910
Aufrufe heute: 6
Gesamt: 73.248
Gesamt: 73.248
Aktive User: 0
ISIN: DE000A3E5C24 · WKN: A3E5C2 · Symbol: CDZ0
1,2800
EUR
-0,78 %
-0,0100 EUR
Letzter Kurs 20.05.24 Baader Bank
Neuigkeiten
23.04.24 · mwb research AG |
18.04.24 · wO Newsflash |
18.04.24 · EQS Group AG |
08.02.24 · mwb research AG |
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2500 | +25,00 | |
| 2,4750 | +23,75 | |
| 20,860 | +16,73 | |
| 6,3200 | +15,75 | |
| 18,900 | +14,89 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 26,00 | -16,13 | |
| 1.200,00 | -16,38 | |
| 6,3000 | -31,97 | |
| 8,0000 | -33,05 | |
| 10,500 | -39,38 |
Beitrag zu dieser Diskussion schreiben
Feedback
27 March 2020
Melissa Kostopoulos
Australian Securities Exchange
Compliance Adviser, Listings Compliance (Melbourne)
Dear Melissa
Response to ASX query
Lifespot Health Limited (LSH or Company) refers to your letter dated 26 March 2020 and responds as follows:
1. Is LSH aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
No.
2. If the answer to question 1 is “yes”.
Not applicable.
3. If the answer to question 1 is “no”, is there any other explanation that LSH may have for the recent trading in its securities?
The Company released an announcement to ASX at 9am on 25 March 2020 (titled “BODYTELTM PLATFORM TO BE EXTENDED TO FEVER TRACKING”) which outlined the Company’s steps to extend the BodyTel digital health monitoring platform to incorporate Bluetooth enabled thermometers to support fever monitoring by individuals and organisations in response to the unmet need arising from the COVID-19 pandemic.
The change in the Company’s share price and increase in trading volumes occurred after the release of this announcement. The Company considers that the market’s response to this announcement explains the recent trading in its securities.
4. In relation to the Announcement please provide:
(a) Details of the ‘Australian and International resources to further develop and complete the BodyTelTM APP and platform extension to incorporate temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer’ said to have been deployed and when it is expected to be completed, as referred to in Statement 1.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
In 2017 and 2018 the Company’s BodyTelTM ISO 13485 accredited platform and APP’s were developed and deployed with connected bluetooth devices to assist patients and their healthcare professionals in the management of chronic metabolic syndrome diseases such as cardiovascular disease and diabetes. These diseases require ongoing tracking of blood pressure, pulse, international normalise ratio (INR), blood sugar and body weight, amongst other parameters.
The Company made a substantial investment in the development of the BodyTelTM platform, however due to competitive pressure and the changing environment in the healthcare system, the revenue expected from utilising the BodyTelTM platform in the management of metabolic syndrome disease has not yet been realised.
The Company did not previously consider body temperature, or tracking of a patient fever, as an important measure for metabolic syndrome diseases and therefore did not develop a Bluetooth connected device for temperature tracking in the suite of its current devices.
However, with the rapid rise of COVID-19 the Company has received enquiries from a Pharmacy distributor and a Pharmacist enquiring as to the availability of body temperature devices with Bluetooth connectivity.
In addition, the Australian Government recently announced as part of its COVID-19 measures the expansion of MBS Telehealth items with a focus on the need for remote monitoring. The Company believes the BodyTelTM platform and its connected Bluetooth device can greatly assist Healthcare practitioners by enabling remote diagnostic data to the Telehealth practitioner.
The Company reviewed the overall market opportunity and decided to focus efforts on adding a range of body temperature devices to the BodyTelTM platform with the intention of having the first devices in market by winter 2020 in Australia.
The Company has therefore engaged with a TGA regulatory consultant to advise on the TGA regulatory approval processes for the products in development and has engaged with software developers in Australia in order to prepare the Bodytel APP and platform to integrate body temperature thermometers.
The Company has also re-engaged the BodyTelTM platform software architect in Germany to provide the Australian software developers with on-boarding to facilitate the local development and enhancement of the technology platform, and to connect the Company to several body temperature thermometer manufacturers in China and Europe to source an existing range of Bluetooth devices branded with the Company’s chosen brand name.
The Company has also engaged with its legal advisors in relation to intellectual property rights protection for its intended product branding.
The Company has made strong progress in sourcing and plans to source suitable devices that are existing on the market and adapt the software platform locally. The Company’s goal is to have the first product in market in June 2020.
(b) Evidence of ‘negotiation with a pharmacy channel distributor in Australia’ (not for release to the market) and how advanced LSH is with the negotiation as referred to in Statement 2
Evidence and summary of negotiation provided to ASX (not for release to market).
The Company has had ongoing negotiations over the past week with a pharmacy distributor organisation. The Company and the pharmacy distributor are currently negotiating over the cost of servicing pharmacies
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
and the costs of maintaining inventory and shipping for a potential ongoing distribution arrangement for the Company’s products throughout Australia.
5. Please confirm that LSH is complying with the Listing Rules and, in particular, Listing Rule 3.1.
The Company is currently in compliance with the Listing Rules, and in particular, Listing 3.1.
6. Please confirm that LSH’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of LSH with delegated authority from the board to respond to ASX on disclosure matters.
Confirmed. This response has been authorised accordingly.
Mr Justyn Stedwell
Company Secretary
On behalf of the Board of Directors Lifespot Health Limited
Go to www.lifespot-health.com
Follow us on Twitter - @LifespotH
About Lifespot Health Ltd.
CONNECTING HARDWARE WITH SOFTWARE – DIGITAL TECHNOLOGY FOR BETTER HEALTHCARE
Our core expertise is in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to our cloud based ISO13485 accredited BodyTelTM patient management system. Our systems and applications are cloud and smartphone-based and easy to use.
We provide our diagnostic systems and medicine delivery platforms to healthcare enterprises for own branding white label contracts. Our German based BodyTelTM system is based on modern and future-proof internet technology utilizing advanced technologies such as document-based databases and biological neural networks.
Our German based Seng-Vital is specialized in development of hardware in the medical and non-medical Cannabis categories. In 2019 the company launched Medihale®, a digitally integrated medical cannabis vaporiser hardware and software solution that incorporates BodyTelTM App’s to be the world’s first fully integrated vaporising system. The Company continues to lead the way in innovative vaporiser hardware and software for OEM clients.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
26 March 2020 Reference: ODIN16009
Mr Justyn Stedwell Company Secretary
Lifespot Health Ltd 1B/205-207 Johnston Street Fitzroy VIC 3065
By email: justyn@stedwell.com.au
Dear Mr Stedwell
Lifespot Health Ltd (‘LSH’): Price Query
We note the change in the price of LSH’s securities from a closing price of 1.7 cents on 23 March 2020 to a high of 6.9 cents today, prior to the pause in trading imposed at 11.53am AEDT when LSH’s securities had last traded at 6.2 cents.
We also note the very significant increase in the volume of LSH’s securities traded yesterday and this morning which may be attributed to the LSH announcement released on the ASX Market Announcements Platform yesterday, 25 March 2020 at 9:00am AEDT, headed ‘BodyTel Platform to be Extended to Fever Tracking’ (the ‘Announcement’) which included the following statements:
A. . Statement 1:
B. Statement 2:
Request for Information
In light of this, ASX asks LSH to respond separately to each of the following questions and requests for information:
1. Is LSH aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is “yes”.
(a) Is LSH relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in LSH’s securities would suggest to ASX that such information may have ceased to be confidential and therefore LSH may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.
(b) Can an announcement be made immediately? Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).
ASX Limited [[Listings]] ASX Customer Service Centre 131 279 | asx.com.au
For personal use only
(c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is “no”, is there any other explanation that LSH may have for the recent trading in its securities?
4. In relation to the Announcement please provide:
(a) Details of the ‘Australian and International resources to further develop and complete the BodyTelTM APP and platform extension to incorporate temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer’ said to have been deployed and when it is expected to be completed, as referred to in Statement 1.
(b) Evidence of ‘negotiation with a pharmacy channel distributor in Australia’ (not for release to the market) and how advanced LSH is with the negotiation as referred to in Statement 2
5. Please confirm that LSH is complying with the Listing Rules and, in particular, Listing Rule 3.1.
6. Please confirm that LSH’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of LSH with delegated authority from the board to respond to ASX on disclosure matters.
When and where to send your response
This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 12:00 PM AEDT Friday, 27 March 2020. If we do not have your response by then, ASX will likely suspend trading in LSH’s securities under Listing Rule 17.3. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, LSH’s obligation is to disclose the information “immediately”. This may require the information to be disclosed before the deadline set out in the previous paragraph.
ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market. Your response should be sent to me by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.
Listing Rules 3.1 and 3.1A
Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities. Exceptions to this requirement are set out in Listing Rule 3.1A. In responding to this letter, you should have regard to LSH’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B. It should be noted that LSH’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.
Trading halt
LSH’s securities are presently in a trading halt which is due to end no later than the commencement of trading on Monday, 30 March 2020, being the second business day after the halt was granted.
If you are unable to respond to this letter by 9:30am AEDT, Monday 30 March 2020, ASX will likely suspend trading in LSH’s securities under Listing Rule 17.3.
2/3
ASX Customer Service Centre 131 279 | asx.com.au
For personal use only
Enquiries
If you have any queries or concerns about any of the above, please contact me immediately.
Yours sincerely
Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
Melissa Kostopoulos
Australian Securities Exchange
Compliance Adviser, Listings Compliance (Melbourne)
Dear Melissa
Response to ASX query
Lifespot Health Limited (LSH or Company) refers to your letter dated 26 March 2020 and responds as follows:
1. Is LSH aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
No.
2. If the answer to question 1 is “yes”.
Not applicable.
3. If the answer to question 1 is “no”, is there any other explanation that LSH may have for the recent trading in its securities?
The Company released an announcement to ASX at 9am on 25 March 2020 (titled “BODYTELTM PLATFORM TO BE EXTENDED TO FEVER TRACKING”) which outlined the Company’s steps to extend the BodyTel digital health monitoring platform to incorporate Bluetooth enabled thermometers to support fever monitoring by individuals and organisations in response to the unmet need arising from the COVID-19 pandemic.
The change in the Company’s share price and increase in trading volumes occurred after the release of this announcement. The Company considers that the market’s response to this announcement explains the recent trading in its securities.
4. In relation to the Announcement please provide:
(a) Details of the ‘Australian and International resources to further develop and complete the BodyTelTM APP and platform extension to incorporate temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer’ said to have been deployed and when it is expected to be completed, as referred to in Statement 1.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
In 2017 and 2018 the Company’s BodyTelTM ISO 13485 accredited platform and APP’s were developed and deployed with connected bluetooth devices to assist patients and their healthcare professionals in the management of chronic metabolic syndrome diseases such as cardiovascular disease and diabetes. These diseases require ongoing tracking of blood pressure, pulse, international normalise ratio (INR), blood sugar and body weight, amongst other parameters.
The Company made a substantial investment in the development of the BodyTelTM platform, however due to competitive pressure and the changing environment in the healthcare system, the revenue expected from utilising the BodyTelTM platform in the management of metabolic syndrome disease has not yet been realised.
The Company did not previously consider body temperature, or tracking of a patient fever, as an important measure for metabolic syndrome diseases and therefore did not develop a Bluetooth connected device for temperature tracking in the suite of its current devices.
However, with the rapid rise of COVID-19 the Company has received enquiries from a Pharmacy distributor and a Pharmacist enquiring as to the availability of body temperature devices with Bluetooth connectivity.
In addition, the Australian Government recently announced as part of its COVID-19 measures the expansion of MBS Telehealth items with a focus on the need for remote monitoring. The Company believes the BodyTelTM platform and its connected Bluetooth device can greatly assist Healthcare practitioners by enabling remote diagnostic data to the Telehealth practitioner.
The Company reviewed the overall market opportunity and decided to focus efforts on adding a range of body temperature devices to the BodyTelTM platform with the intention of having the first devices in market by winter 2020 in Australia.
The Company has therefore engaged with a TGA regulatory consultant to advise on the TGA regulatory approval processes for the products in development and has engaged with software developers in Australia in order to prepare the Bodytel APP and platform to integrate body temperature thermometers.
The Company has also re-engaged the BodyTelTM platform software architect in Germany to provide the Australian software developers with on-boarding to facilitate the local development and enhancement of the technology platform, and to connect the Company to several body temperature thermometer manufacturers in China and Europe to source an existing range of Bluetooth devices branded with the Company’s chosen brand name.
The Company has also engaged with its legal advisors in relation to intellectual property rights protection for its intended product branding.
The Company has made strong progress in sourcing and plans to source suitable devices that are existing on the market and adapt the software platform locally. The Company’s goal is to have the first product in market in June 2020.
(b) Evidence of ‘negotiation with a pharmacy channel distributor in Australia’ (not for release to the market) and how advanced LSH is with the negotiation as referred to in Statement 2
Evidence and summary of negotiation provided to ASX (not for release to market).
The Company has had ongoing negotiations over the past week with a pharmacy distributor organisation. The Company and the pharmacy distributor are currently negotiating over the cost of servicing pharmacies
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
and the costs of maintaining inventory and shipping for a potential ongoing distribution arrangement for the Company’s products throughout Australia.
5. Please confirm that LSH is complying with the Listing Rules and, in particular, Listing Rule 3.1.
The Company is currently in compliance with the Listing Rules, and in particular, Listing 3.1.
6. Please confirm that LSH’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of LSH with delegated authority from the board to respond to ASX on disclosure matters.
Confirmed. This response has been authorised accordingly.
Mr Justyn Stedwell
Company Secretary
On behalf of the Board of Directors Lifespot Health Limited
Go to www.lifespot-health.com
Follow us on Twitter - @LifespotH
About Lifespot Health Ltd.
CONNECTING HARDWARE WITH SOFTWARE – DIGITAL TECHNOLOGY FOR BETTER HEALTHCARE
Our core expertise is in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to our cloud based ISO13485 accredited BodyTelTM patient management system. Our systems and applications are cloud and smartphone-based and easy to use.
We provide our diagnostic systems and medicine delivery platforms to healthcare enterprises for own branding white label contracts. Our German based BodyTelTM system is based on modern and future-proof internet technology utilizing advanced technologies such as document-based databases and biological neural networks.
Our German based Seng-Vital is specialized in development of hardware in the medical and non-medical Cannabis categories. In 2019 the company launched Medihale®, a digitally integrated medical cannabis vaporiser hardware and software solution that incorporates BodyTelTM App’s to be the world’s first fully integrated vaporising system. The Company continues to lead the way in innovative vaporiser hardware and software for OEM clients.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
26 March 2020 Reference: ODIN16009
Mr Justyn Stedwell Company Secretary
Lifespot Health Ltd 1B/205-207 Johnston Street Fitzroy VIC 3065
By email: justyn@stedwell.com.au
Dear Mr Stedwell
Lifespot Health Ltd (‘LSH’): Price Query
We note the change in the price of LSH’s securities from a closing price of 1.7 cents on 23 March 2020 to a high of 6.9 cents today, prior to the pause in trading imposed at 11.53am AEDT when LSH’s securities had last traded at 6.2 cents.
We also note the very significant increase in the volume of LSH’s securities traded yesterday and this morning which may be attributed to the LSH announcement released on the ASX Market Announcements Platform yesterday, 25 March 2020 at 9:00am AEDT, headed ‘BodyTel Platform to be Extended to Fever Tracking’ (the ‘Announcement’) which included the following statements:
A. . Statement 1:
B. Statement 2:
Request for Information
In light of this, ASX asks LSH to respond separately to each of the following questions and requests for information:
1. Is LSH aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is “yes”.
(a) Is LSH relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in LSH’s securities would suggest to ASX that such information may have ceased to be confidential and therefore LSH may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is “yes”, you need to contact us immediately to discuss the situation.
(b) Can an announcement be made immediately? Please note, if the answer to this question is “no”, you need to contact us immediately to discuss requesting a trading halt (see below).
ASX Limited [[Listings]] ASX Customer Service Centre 131 279 | asx.com.au
For personal use only
(c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is “no”, is there any other explanation that LSH may have for the recent trading in its securities?
4. In relation to the Announcement please provide:
(a) Details of the ‘Australian and International resources to further develop and complete the BodyTelTM APP and platform extension to incorporate temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer’ said to have been deployed and when it is expected to be completed, as referred to in Statement 1.
(b) Evidence of ‘negotiation with a pharmacy channel distributor in Australia’ (not for release to the market) and how advanced LSH is with the negotiation as referred to in Statement 2
5. Please confirm that LSH is complying with the Listing Rules and, in particular, Listing Rule 3.1.
6. Please confirm that LSH’s responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of LSH with delegated authority from the board to respond to ASX on disclosure matters.
When and where to send your response
This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than 12:00 PM AEDT Friday, 27 March 2020. If we do not have your response by then, ASX will likely suspend trading in LSH’s securities under Listing Rule 17.3. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, LSH’s obligation is to disclose the information “immediately”. This may require the information to be disclosed before the deadline set out in the previous paragraph.
ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market. Your response should be sent to me by e-mail at ListingsComplianceMelbourne@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.
Listing Rules 3.1 and 3.1A
Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity’s securities. Exceptions to this requirement are set out in Listing Rule 3.1A. In responding to this letter, you should have regard to LSH’s obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B. It should be noted that LSH’s obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.
Trading halt
LSH’s securities are presently in a trading halt which is due to end no later than the commencement of trading on Monday, 30 March 2020, being the second business day after the halt was granted.
If you are unable to respond to this letter by 9:30am AEDT, Monday 30 March 2020, ASX will likely suspend trading in LSH’s securities under Listing Rule 17.3.
2/3
ASX Customer Service Centre 131 279 | asx.com.au
For personal use only
Enquiries
If you have any queries or concerns about any of the above, please contact me immediately.
Yours sincerely
Melissa Kostopoulos
Compliance Adviser, Listings Compliance (Melbourne)
Antwort auf Beitrag Nr.: 63.122.212 von peter81379 am 25.03.20 08:34:02
https://www.pressetext.com/news/20200325009
Lifespot und Coronavirus
Lifespot Capital AG: Lifespot Health Ltd. erweitert Telemedizinplattform um bluetoothfähige Fieberthermometer im Kampf gegen Pandemienhttps://www.pressetext.com/news/20200325009
ASX ANNOUNCEMENT
BODYTELTM PLATFORM TO BE EXTENDED TO FEVER TRACKING Lifespot Health Limited ASX:LSH 25th March 2020
• LSH BodyTelTM platform being extended to incorporate Bluetooth enabled thermometers to support self and organisational monitoring
• Currently a large unmet need globally for fever tracking as a result of the COVID-19 pandemic
• Ongoing self-monitoring and community tracking seen as a significant contributor to reduce the
impact of COVID-19
• Negotiations underway with pharmacy channel distributor in Australia for first market launch
Following market requests for a fully integrated temperature self-tracking and monitoring system for individuals and organisations, the Company has deployed Australian and International resources to further develop and complete the BodyTelTM APP and platform extension to incorporate temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer.
The current Australian government guidelines for COVID-19 recommend ongoing self-monitoring of symptoms including fever, coughing, sore throat, fatigue and shortness of breath.
When checking for fever, most of the current digital thermometers in the marketplace only keep a short series of historical data which is not visually represented to enable easy tracking. In addition, this data is not able to be aggregated* to provide community, organization or geographical reporting.
Recent studies1 in the USA have shown that smart thermometers can be a new source of information for flu surveillance and forecasting, allowing for more rapid and efficient disease management. In countries like Singapore and Hong Kong it is believed their approach to ongoing self-tracking and community tracking has been a significant driver of the ability to reduce the impact of COVID-19.
The Company notes that the COVID-19 at risk patients can be those with Cardiovascular Disease or Diabetes. The Bodytel® System already has the capability to track blood sugar, ECG, blood pressure and weight via the existing Bluetooth connected devices. Extending the platform to track fever via body temperature is a commercially low risk, yet logical extension to the platform and can currently address the large unmet need globally for this function arising from the COVID-19 pandemic.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
The Company is currently in negotiation with a pharmacy channel distributor in Australia to begin the Australian and then Asia Pacific regional rollout.
The Company’s BodyTelTM Smart Phone APP will provide individuals or families with ongoing body temperature tracking, and the Bodytel cloud-based platform will provide aggregated data* for designated groups, communities and organisations to track their designated groups data whilst protecting individual’s privacy.
The Company will provide further updates in due course.
*subject to individual consent to share their data into the aggregated dataset.
1. Miller AC, Singh I, Koehler E, Polgreen PM. A Smartphone-Driven Thermometer Application for Real-time Population- and Individual-Level Influenza Surveillance. Clin Infect Dis. 2018;67:388–97.
Mr Justyn Stedwell
Company Secretary (03) 9191 0135
Go to www.lifespot-health.com Follow us on Twitter - @LifespotH
About Lifespot Health Ltd.
CONNECTING HARDWARE WITH SOFTWARE – DIGITAL TECHNOLOGY FOR BETTER HEALTHCARE
Our core expertise is in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to our cloud based ISO13485 accredited BodyTelTM patient management system. Our systems and applications are cloud and smartphone-based and easy to use.
We provide our diagnostic systems and medicine delivery platforms to healthcare enterprises for own branding white label contracts. Our German based BodyTelTM system is based on modern and future-proof internet technology utilizing advanced technologies such as document-based databases and biological neural networks.
Our German based Seng-Vital is specialized in development of hardware in the medical and non-medical Cannabis categories. In 2019 the company launched Medihale®, a digitally integrated medical cannabis vaporiser hardware and software solution that incorporates BodyTelTM App’s to be the world’s first fully integrated vaporising system. The Company continues to lead the way in innovative vaporiser hardware and software for OEM clients.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
BODYTELTM PLATFORM TO BE EXTENDED TO FEVER TRACKING Lifespot Health Limited ASX:LSH 25th March 2020
• LSH BodyTelTM platform being extended to incorporate Bluetooth enabled thermometers to support self and organisational monitoring
• Currently a large unmet need globally for fever tracking as a result of the COVID-19 pandemic
• Ongoing self-monitoring and community tracking seen as a significant contributor to reduce the
impact of COVID-19
• Negotiations underway with pharmacy channel distributor in Australia for first market launch
Following market requests for a fully integrated temperature self-tracking and monitoring system for individuals and organisations, the Company has deployed Australian and International resources to further develop and complete the BodyTelTM APP and platform extension to incorporate temperature monitoring via the Bodytel platform and a branded Bluetooth thermometer.
The current Australian government guidelines for COVID-19 recommend ongoing self-monitoring of symptoms including fever, coughing, sore throat, fatigue and shortness of breath.
When checking for fever, most of the current digital thermometers in the marketplace only keep a short series of historical data which is not visually represented to enable easy tracking. In addition, this data is not able to be aggregated* to provide community, organization or geographical reporting.
Recent studies1 in the USA have shown that smart thermometers can be a new source of information for flu surveillance and forecasting, allowing for more rapid and efficient disease management. In countries like Singapore and Hong Kong it is believed their approach to ongoing self-tracking and community tracking has been a significant driver of the ability to reduce the impact of COVID-19.
The Company notes that the COVID-19 at risk patients can be those with Cardiovascular Disease or Diabetes. The Bodytel® System already has the capability to track blood sugar, ECG, blood pressure and weight via the existing Bluetooth connected devices. Extending the platform to track fever via body temperature is a commercially low risk, yet logical extension to the platform and can currently address the large unmet need globally for this function arising from the COVID-19 pandemic.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
For personal use only
The Company is currently in negotiation with a pharmacy channel distributor in Australia to begin the Australian and then Asia Pacific regional rollout.
The Company’s BodyTelTM Smart Phone APP will provide individuals or families with ongoing body temperature tracking, and the Bodytel cloud-based platform will provide aggregated data* for designated groups, communities and organisations to track their designated groups data whilst protecting individual’s privacy.
The Company will provide further updates in due course.
*subject to individual consent to share their data into the aggregated dataset.
1. Miller AC, Singh I, Koehler E, Polgreen PM. A Smartphone-Driven Thermometer Application for Real-time Population- and Individual-Level Influenza Surveillance. Clin Infect Dis. 2018;67:388–97.
Mr Justyn Stedwell
Company Secretary (03) 9191 0135
Go to www.lifespot-health.com Follow us on Twitter - @LifespotH
About Lifespot Health Ltd.
CONNECTING HARDWARE WITH SOFTWARE – DIGITAL TECHNOLOGY FOR BETTER HEALTHCARE
Our core expertise is in connecting medical diagnostic devices and digital medicine delivery systems via Bluetooth and Smart device APPs to our cloud based ISO13485 accredited BodyTelTM patient management system. Our systems and applications are cloud and smartphone-based and easy to use.
We provide our diagnostic systems and medicine delivery platforms to healthcare enterprises for own branding white label contracts. Our German based BodyTelTM system is based on modern and future-proof internet technology utilizing advanced technologies such as document-based databases and biological neural networks.
Our German based Seng-Vital is specialized in development of hardware in the medical and non-medical Cannabis categories. In 2019 the company launched Medihale®, a digitally integrated medical cannabis vaporiser hardware and software solution that incorporates BodyTelTM App’s to be the world’s first fully integrated vaporising system. The Company continues to lead the way in innovative vaporiser hardware and software for OEM clients.
Lifespot Health Limited (ACN 611 845 820) 1B/205-207 Johnston St Fitzroy VIC 3065 (03) 9191 0135
Antwort auf Beitrag Nr.: 57.754.522 von Selectplus am 14.05.18 14:47:46
Seng Vital
https://www.asx.com.au/asxpdf/20180620/pdf/43vx2p9255f4lv.pd… Trading Spotlight
Antwort auf Beitrag Nr.: 57.754.522 von Selectplus am 14.05.18 14:47:46
es geht hier weiter
https://www.asx.com.au/asxpdf/20180605/pdf/43vk3wg27cb37n.pd…
Cannabis-Tochter nimmt Fahrt auf
https://smallcaps.com.au/lifespot-health-israel-medical-cann…
Lifespot Health edges into Israel’s medical cannabis space with Seng Vital vaporiser
Digital health provider Lifespot Health (ASX: LSH) is edging into Israel’s medical cannabis market after entering discussions to have its Seng Vital vaporiser, which comprises the certified BodyTel software platform, used in upcoming clinical trials that Israel-based companies are carrying out with a view to commercialising the product in the region.
Lifespot’s 50%-owned subsidiary Seng Vital developed the vaporiser which is activated by a patient’s finger print. Once it is activated, the vaporiser allows cannabis to be inhaled from oils or herbs.
The Bluetooth enabled vaporiser has been integrated with Lifespot’s wholly-owned subsidiary BodyTel’s Monitoring and Collection software platform. The software gathers and collates data and readings from the vaporiser, which patients and their authorised physicians can then review and evaluate.
In addition to the device’s finger print security feature, active ingredient medical cannabis capsules contain a central pharmaceutical number to ensure authorised use.
Lifespot claims the security features makes the vaporiser more likely to be recognised as a medical device by the US Food and Drug Administration.
“Due to the exact dosage and complete monitoring by means of our certified BodyTel platform, that has already been tested by several well-known medical device manufacturers, we will bring a product to the market which meets all requirements for a medical device,” Lifespot executive director Heiner Emden said.
Israel and medical cannabis market
Mr Emden said the company’s strategy behind its entry into Israel was because Israel is one of the “world’s leading epicentres” for cannabis research and development.
He said the country was leading the way in the evolution of the medical cannabis market.
“We are delighted to be here talking to the leading players in cannabis and see strong potential for our integrated system as an enabler for clinical studies and commercialisation,” added Mr Emden, who is also the managing director of BodyTel said.
Global medical cannabis market
According to Lifespot, its Seng Vital device with the integrated BodyTel technology has a “huge growth market”.
Lifespot cites Arcview Market Research and BSD Analytics, which projects the world market for legal cannabis applications will be worth more than US$57 billion by 2027, with medical cannabis applications to account for US$19 billion of that market.
In early afternoon trade, Lifespot’s share price had risen almost 8% to A$0.14.
https://smallcaps.com.au/lifespot-health-israel-medical-cann…
Lifespot Health edges into Israel’s medical cannabis space with Seng Vital vaporiser
Digital health provider Lifespot Health (ASX: LSH) is edging into Israel’s medical cannabis market after entering discussions to have its Seng Vital vaporiser, which comprises the certified BodyTel software platform, used in upcoming clinical trials that Israel-based companies are carrying out with a view to commercialising the product in the region.
Lifespot’s 50%-owned subsidiary Seng Vital developed the vaporiser which is activated by a patient’s finger print. Once it is activated, the vaporiser allows cannabis to be inhaled from oils or herbs.
The Bluetooth enabled vaporiser has been integrated with Lifespot’s wholly-owned subsidiary BodyTel’s Monitoring and Collection software platform. The software gathers and collates data and readings from the vaporiser, which patients and their authorised physicians can then review and evaluate.
In addition to the device’s finger print security feature, active ingredient medical cannabis capsules contain a central pharmaceutical number to ensure authorised use.
Lifespot claims the security features makes the vaporiser more likely to be recognised as a medical device by the US Food and Drug Administration.
“Due to the exact dosage and complete monitoring by means of our certified BodyTel platform, that has already been tested by several well-known medical device manufacturers, we will bring a product to the market which meets all requirements for a medical device,” Lifespot executive director Heiner Emden said.
Israel and medical cannabis market
Mr Emden said the company’s strategy behind its entry into Israel was because Israel is one of the “world’s leading epicentres” for cannabis research and development.
He said the country was leading the way in the evolution of the medical cannabis market.
“We are delighted to be here talking to the leading players in cannabis and see strong potential for our integrated system as an enabler for clinical studies and commercialisation,” added Mr Emden, who is also the managing director of BodyTel said.
Global medical cannabis market
According to Lifespot, its Seng Vital device with the integrated BodyTel technology has a “huge growth market”.
Lifespot cites Arcview Market Research and BSD Analytics, which projects the world market for legal cannabis applications will be worth more than US$57 billion by 2027, with medical cannabis applications to account for US$19 billion of that market.
In early afternoon trade, Lifespot’s share price had risen almost 8% to A$0.14.
man beachte die LSH announcements
https://www.asx.com.au/asx/share-price-research/company/LSH
https://www.asx.com.au/asx/share-price-research/company/LSH
ist das etwas im Busch...???
seit 3 Monaten wurden nun um die 300.000 Lifespot Capital AG Aktien abgestaubt ???
Lifespot Capital AG: Wechsel im Aufsichtsrat
Lifespot Capital AG / Schlagwort(e): Personalie
18.07.2017 / 14:09 CET/CEST
Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR, übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
München, 18.07.2017 - Die Lifespot Capital AG gibt bekannt, dass das bisherige, von der Hauptversammlung gewählte Mitglied des Aufsichtsrates der Gesellschaft, Herr Dr. Peter Görlich, planmäßig sein Amt als Aufsichtsratsmitglied der Gesellschaft durch Schreiben mit sofortiger Wirkung niedergelegt hat.
Um die Beschlussfähigkeit des Aufsichtsrates der Gesellschaft bis zur nächsten Hauptversammlung wiederherzustellen, erscheint für den Zeitraum bis zur Neuwahl eines Aufsichtsratsmitglieds durch die Hauptversammlung eine gerichtliche Bestellung eines neuen Aufsichtsratsmitglieds geboten.
Der Vorstand schlägt daher vor, dass Herr Francesco Cannavo gemäß § 104 Abs. 1 AktG für die Zeit bis zur Wahl eines neuen Aufsichtsratsmitglieds durch die Hauptversammlung der Gesellschaft gerichtlich zum Mitglied des Aufsichtsrats der Gesellschaft zu bestellen.
München, 18. Juli 2017
Lifespot Capital AG - Der Vorstand
Informationen und Erläuterungen des Emittenten zu dieser Mitteilung:
Kontakt Lifespot Capital AG:
Andreas Empl
Vorstand
Denisstr. 1b
D-80335 München
Tel:+49 - 89-244-192-200
Fax: +49 - 89-244-192-230
www.lifespotcapital.com
Lifespot Capital AG / Schlagwort(e): Personalie
18.07.2017 / 14:09 CET/CEST
Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR, übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
München, 18.07.2017 - Die Lifespot Capital AG gibt bekannt, dass das bisherige, von der Hauptversammlung gewählte Mitglied des Aufsichtsrates der Gesellschaft, Herr Dr. Peter Görlich, planmäßig sein Amt als Aufsichtsratsmitglied der Gesellschaft durch Schreiben mit sofortiger Wirkung niedergelegt hat.
Um die Beschlussfähigkeit des Aufsichtsrates der Gesellschaft bis zur nächsten Hauptversammlung wiederherzustellen, erscheint für den Zeitraum bis zur Neuwahl eines Aufsichtsratsmitglieds durch die Hauptversammlung eine gerichtliche Bestellung eines neuen Aufsichtsratsmitglieds geboten.
Der Vorstand schlägt daher vor, dass Herr Francesco Cannavo gemäß § 104 Abs. 1 AktG für die Zeit bis zur Wahl eines neuen Aufsichtsratsmitglieds durch die Hauptversammlung der Gesellschaft gerichtlich zum Mitglied des Aufsichtsrats der Gesellschaft zu bestellen.
München, 18. Juli 2017
Lifespot Capital AG - Der Vorstand
Informationen und Erläuterungen des Emittenten zu dieser Mitteilung:
Kontakt Lifespot Capital AG:
Andreas Empl
Vorstand
Denisstr. 1b
D-80335 München
Tel:+49 - 89-244-192-200
Fax: +49 - 89-244-192-230
www.lifespotcapital.com
Durchsuchen
23.04.24 · mwb research AG · MHP Hotel |
18.04.24 · wO Newsflash · MHP Hotel |
18.04.24 · EQS Group AG · MHP Hotel |
08.02.24 · mwb research AG · MHP Hotel |
07.02.24 · 4investors · MHP Hotel |
07.02.24 · EQS Group AG · MHP Hotel |
29.01.24 · Aktien Global · MHP Hotel |
25.01.24 · mwb research AG · MHP Hotel |
25.01.24 · EQS Group AG · MHP Hotel |
20.11.23 · mwb research AG · MHP Hotel |